Diadema Partners LP Makes New Investment in argenx SE (NASDAQ:ARGX)

Diadema Partners LP bought a new position in shares of argenx SE (NASDAQ:ARGX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 679 shares of the company's stock, valued at approximately $422,000.

A number of other hedge funds have also recently bought and sold shares of the company. Stephens Inc. AR acquired a new position in shares of argenx in the fourth quarter worth about $310,000. Ritholtz Wealth Management raised its stake in shares of argenx by 85.5% in the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company's stock valued at $552,000 after acquiring an additional 414 shares in the last quarter. Jones Financial Companies Lllp lifted its stake in shares of argenx by 1,016.7% in the fourth quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock worth $41,000 after buying an additional 61 shares during the last quarter. Park Avenue Securities LLC lifted its position in argenx by 40.0% during the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company's stock worth $1,042,000 after acquiring an additional 484 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in argenx in the 3rd quarter worth approximately $652,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Oppenheimer upped their price target on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a report on Friday, February 28th. JMP Securities upped their target price on shares of argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Truist Financial reiterated a "buy" rating and set a $700.00 price target (up previously from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a research note on Wednesday, March 12th. Finally, Guggenheim raised their price target on argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $699.28.

argenx Stock Up 2.4 %

Shares of NASDAQ ARGX traded up $14.25 during mid-day trading on Friday, reaching $614.76. 215,836 shares of the company were exchanged, compared to its average volume of 308,133. The stock has a market capitalization of $37.54 billion, a P/E ratio of -698.59 and a beta of 0.60. argenx SE has a twelve month low of $352.77 and a twelve month high of $678.21. The company's 50-day simple moving average is $598.28 and its 200-day simple moving average is $608.44.

argenx (NASDAQ:ARGX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. As a group, equities research analysts expect that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.